Topic: age-related macular degeneration
Investors had been worried that growth for Regeneron’s Eylea was slowing down, but Monday the company batted away those fears.
The eye drug star has nabbed an FDA nod as a 12-week formulation in wet AMD and is expected to get into diabetic retinopathy next May.
The latest data from trials of Novartis's RTH258 to treat macular degeneration suggest it could be a threat to Regeneron's blockbuster Eylea.
Regeneron’s flagship med Eylea fell short of sales expectations in Q1, raising questions as Praluent idles and potential big-earner Dupixent makes its debut.